The challenges of treating aspergillus abdominal aneurysm after hematopoietic cell transplant: Rapid voriconazole metabolizer

Abstract

Mycotic aneurysms are a fatal manifestation of disseminated fungal infections in immunocompromised hosts. We present a patient with an Aspergillus mycotic aneurysm after hematopoietic cell transplant. Due to CYP2C19 rapid metabolizer phenotype (*1/*17), therapeutic levels of voriconazole were unobtainable. Successful therapy was achieved with posaconazole salvage therapy and early, aggressive surgery. This case demonstrates the consequences of voriconazole rapid metabolism and the potential impact of genetic variants.

Keywords

Aspergillus CYP2C19 posaconazole rapid metabolism voriconazole

Get full access to this article

View all access options for this article.

References

Ustun

Arock

Kluin-Nelemans

et al.

Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica 2016; 101: 1133–1143.

Ustun

Gotlib

Popat

et al.

Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transplant 2016; 22: 1348–1356.

Ustun

Reiter

Scott

et al.

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014; 32: 3264–3274.

xTAG® CYP2C19 Kit v3 [package insert]. Luminex Corporation, Austin, TX, 2013.

Patterson

Thompson

3rd Denning

et al.

Diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63: e1–e60.

Ashbee

Barnes

Johnson

et al.

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69: 1162–1176.

Hyland

Jones

Smith

. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31: 540–547.

Desta

Zhao

Shin

et al.

Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913–958.

Wang

et al.

Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. Eur J Clin Pharmacol 2016; 72: 1185–1193.

10.

Wang

Lei

et al.

The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009; 65: 281–285.

11.

Moriyama B, Obeng AO, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. Epub ahead of print 16 December 2016. DOI: 10.1002/cpt.583.

12.

Berge

Guillemain

Trégouet

et al.

Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol 2011; 67: 253–260.

13.

Trubiano

Crowe

Worth

et al.

Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. J Antimicrob Chemother 2015; 70: 1161–1165.

14.

Abidi

D’Souza

Kuppalli

et al.

CYP2C19*17 genetic polymorphism – an uncommon cause of voriconazole treatment failure. Diagn Microbiol Infect Dis 2015; 83: 46–48.

15.

Ghosal

Hapangama

Yuan

et al.

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004; 32: 267–271.